{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:40:35Z","timestamp":1767854435516,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.06.024","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T20:11:04Z","timestamp":1529352664000},"page":"4462-4470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses"],"prefix":"10.1016","volume":"36","author":[{"given":"Marija","family":"Vujadinovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Oosterhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taco G.","family":"Uil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarra","family":"Damman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Boedhoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek","family":"Verwilligen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Scheper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Custers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jort","family":"Vellinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.06.024_b0005","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 3:S3","key":"10.1016\/j.vaccine.2018.06.024_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 10","key":"10.1016\/j.vaccine.2018.06.024_b0015","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.024_b0020","unstructured":"International Agency for Research on Cancer IARC Monographs on the Evaluation of Carcinogenic Risks to Humans NB, (FR) IWGotEoCRtHL. Biological Agents: Human Papillomaviruses; 2012."},{"key":"10.1016\/j.vaccine.2018.06.024_b0025","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.06.024_b0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.06.024_b0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0040","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jnci\/djs395","article-title":"Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis","volume":"104","author":"Van de Velde","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2018.06.024_b0045","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1128\/JVI.01927-09","article-title":"Papillomavirus prophylactic vaccines: established successes, new approaches","volume":"84","author":"Campo","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/icb.2009.13","article-title":"Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection","volume":"87","author":"Karanam","year":"2009","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"Wang","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.024_b0060","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0065","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2018.06.024_b0070","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2","volume":"105","author":"Alphs","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2018.06.024_b0075","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2008.11.099","article-title":"Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity","volume":"27","author":"Karanam","year":"2009","journal-title":"Vaccine"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2018.06.024_b0080","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1099\/0022-1317-74-6-945","article-title":"Prophylactic and therapeutic vaccination against a mucosal papillomavirus","volume":"74","author":"Campo","year":"1993","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0090","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1038\/srep04729","article-title":"A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope","volume":"4","author":"Canali","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.06.024_b0095","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1128\/JVI.77.15.8386-8393.2003","article-title":"Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16","volume":"77","author":"Varsani","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0100","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1\u2013L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines","volume":"83","author":"Schellenbacher","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0105","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.vaccine.2015.05.016","article-title":"Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2","volume":"33","author":"Tumban","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.024_b0110","doi-asserted-by":"crossref","first-page":"e23310","DOI":"10.1371\/journal.pone.0023310","article-title":"A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2","volume":"6","author":"Tumban","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0115","doi-asserted-by":"crossref","first-page":"e49751","DOI":"10.1371\/journal.pone.0049751","article-title":"VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus","volume":"7","author":"Tumban","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0120","doi-asserted-by":"crossref","first-page":"e39741","DOI":"10.1371\/journal.pone.0039741","article-title":"Development of AAVLP(HPV16\/31L2) particles as broadly protective HPV vaccine candidate","volume":"7","author":"Nieto","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12985-015-0364-7","article-title":"Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach","volume":"12","author":"Wu","year":"2015","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.06.024_b0130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2018.06.024_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041936","article-title":"A Phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"Keefer","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.06.024_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"Ouedraogo","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0150","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.vaccine.2018.06.024_b0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/mp100214b","article-title":"Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach","volume":"8","author":"Matthews","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2018.06.024_b0160","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1128\/JVI.01840-09","article-title":"Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection","volume":"84","author":"Bayer","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0165","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/hum.2009.148","article-title":"Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid","volume":"21","author":"Boyer","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2018.06.024_b0170","doi-asserted-by":"crossref","first-page":"e0174728","DOI":"10.1371\/journal.pone.0174728","article-title":"Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform","volume":"12","author":"Salisch","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0175","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0180","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.024_b0185","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0190","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0195","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2018.06.024_b0205","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1021\/op500244f","article-title":"Batch-to-batch variation: a key component for modeling chemical manufacturing processes","volume":"19","author":"Mockus","year":"2015","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.vaccine.2018.06.024_b0210","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1128\/JVI.02667-05","article-title":"Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity","volume":"80","author":"Krause","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0215","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/vir.0.83119-0","article-title":"High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector","volume":"88","author":"Vogels","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0220","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1016\/j.vaccine.2005.04.023","article-title":"Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency","volume":"23","author":"Wang","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.024_b0225","first-page":"445","article-title":"Generation of HPV pseudovirions using transfection and their use in neutralization assays","volume":"119","author":"Buck","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.vaccine.2018.06.024_b0230","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/CVI.00139-12","article-title":"A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies","volume":"19","author":"Day","year":"2012","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.06.024_b0235","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/emboj\/20.10.2587","article-title":"Replication slippage involves DNA polymerase pausing and dissociation","volume":"20","author":"Viguera","year":"2001","journal-title":"Embo J"},{"key":"10.1016\/j.vaccine.2018.06.024_b0240","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.mrfmmm.2006.01.020","article-title":"Mechanisms of tandem repeat instability in bacteria","volume":"598","author":"Bichara","year":"2006","journal-title":"Mutat Res-Fund Mol M"},{"key":"10.1016\/j.vaccine.2018.06.024_b0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/10_008","article-title":"Production and formulation of adenovirus vectors","volume":"99","author":"Altaras","year":"2005","journal-title":"Adv Biochem Eng\/Biotechnol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0250","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2010.10.017","article-title":"The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies","volume":"409","author":"Rubio","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.024_b0255","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1743-422X-10-108","article-title":"Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice","volume":"10","author":"Johrden","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.06.024_b0260","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"Richards","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2018.06.024_b0265","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1128\/JVI.76.14.6893-6899.2002","article-title":"Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX","volume":"76","author":"Dmitriev","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0270","unstructured":"Adriaansen J. Improved adenovirus formulations. In: CH BV, editor. Leiden, The Netherlands: Janssen Vaccines and Prevention BV; 2018. Patent US9974737B2."},{"key":"10.1016\/j.vaccine.2018.06.024_b0275","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1128\/JVI.03218-12","article-title":"Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine","volume":"87","author":"Jagu","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.024_b0280","doi-asserted-by":"crossref","first-page":"e55538","DOI":"10.1371\/journal.pone.0055538","article-title":"Optimization of multimeric human papillomavirus L2 vaccines","volume":"8","author":"Jagu","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.06.024_b0285","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.024_b0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.virol.2005.04.011","article-title":"Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2","volume":"337","author":"Pastrana","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.024_b0295","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1016\/S0264-410X(03)00454-7","article-title":"Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers","volume":"21","author":"Kawana","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.024_b0300","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1158\/0008-5472.CAN-06-2560","article-title":"Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species","volume":"66","author":"Gambhira","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.06.024_b0305","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0264-410X(00)00367-4","article-title":"Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies","volume":"19","author":"Kawana","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.024_b0310","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18308405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18308405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T16:47:38Z","timestamp":1530031658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18308405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":62,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18308405"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}